Search

Your search keyword '"Beneduce A"' showing total 19 results
Start Over Author "Beneduce A" Journal digestive and liver disease
19 results on '"Beneduce A"'

2. P.18.23 SCCA-IgM: A BIOMARKER TO MONITOR THE OUTCOME OF THERAPY WITH SORAFENIB IN ADVANCED HCC

Author

Nicola Caporaso, Francesco Auriemma, R. Tortora, Michele Pier Luca Guarino, C. Ferraiuoli, Ilaria Loperto, L. Beneduce, Concetta Tuccillo, Filomena Morisco, and G.G. Di Costanzo

Subjects
Sorafenib, Oncology, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, Biomarker (medicine), business, medicine.drug
Published
2013
Full Text
View/download PDF

3. P.17.9 TELAPREVIR- OR BOCEPREVIR-BASED TRIPLE-THERAPY IN PATIENTS WITH HCV INFECTION GENOTYPE 1: ON-TREATMENT EFFICACY AND DATA ON SAFETY

Author

Federico, A., primary, Cotticelli, G., additional, De Simini, G., additional, Gravina, A.G., additional, Miranda, A., additional, Sgambato, D., additional, Dallio, M., additional, De Sio, C., additional, Ferrante, E., additional, Meucci, R., additional, Rossetti, G., additional, Vitale, L.M., additional, Beneduce, F., additional, Romano, M., additional, and Loguercio, C., additional

Published
2014
Full Text
View/download PDF

4. P.17.9 TELAPREVIR- OR BOCEPREVIR-BASED TRIPLE-THERAPY IN PATIENTS WITH HCV INFECTION GENOTYPE 1: ON-TREATMENT EFFICACY AND DATA ON SAFETY

Author

Antonietta Gerarda Gravina, Gianluca Rossetti, C. De Sio, Marcello Dallio, Agnese Miranda, Alessandro Federico, Carmela Loguercio, Maurizio Romano, E. Ferrante, Lorenza Vitale, Gaetano Cotticelli, R. Meucci, F. Beneduce, D. Sgambato, and G. De Simini

Subjects
medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, Treatment efficacy, Telaprevir, chemistry.chemical_compound, chemistry, Internal medicine, Boceprevir, Genotype, medicine, In patient, business, medicine.drug
Published
2014
Full Text
View/download PDF

5. Osteopontin-IgM in the diagnosis of HCC

Author

M. T. Aldinio, J. Zuin, Angelo Gatta, D. Paccagnella, M. Mazzucco, Fabio Farinati, L. Franzosi, L. Beneduce, Alessandra Biasiolo, E Miola, N. Tono, Giorgio Fassina, A. Giacomin, Patrizia Pontisso, S. Meo, V. Vanin, and S. Donà

Subjects
Pathology, medicine.medical_specialty, Hepatology, biology, business.industry, medicine.medical_treatment, CD44, Gastroenterology, CD34, Liver transplantation, Antigen, Cancer stem cell, Cell culture, biology.protein, Medicine, Osteopontin, business, Cytometry
Abstract

called cancer stem cells (CSCs). In this study we characterized cell suspensions obtained by dissociation of tumoral (T) and non-tumoral (n-T) liver specimens in order to identify putative liver CSCs. Materials and methods. We included in this study 22 patients undergoing surgical resection (n = 20) and liver transplantation (n = 2) for HCC. Both T and n-T specimens were enzymatically dissociated and single cell suspensions were characterized by 6 color flow cytometry for the following “stemness” antigens: CD34, CD133, ABCG2, Thy-1, EpCAM, c-kit, VGFr-2, CD44, CD49f/29. Moreover, cell suspensions were cultured on collagen coated plastic flask with IMDM and 20% FBS. Results. We included 22 patients (age 35–82, range) with the following cirrhosis etiology: 15 HBV and/or HCV related, 2 alcohol related and 5 cryptogenic. Five out of 20 resected patients underwent tumor relapse in a range of 4–24 months (median 8). No relapse was observed in transplanted patients. Interestingly, we observed a higher but not significant percentage of CD49f/CD29 positive cells in all T than in n-T specimens of relapsed patients (median 1.7% vs. 0.6%; p > 0.05); moreover CD49f/CD29 cells were significantly more frequent in T specimens of relapsed patients than in those of non-relapsed ones (median 1.7% vs. 0.2%, p = 0.01). These cells expressed the ABCG2 protein and were able to generate long term culture cell lines in 3 out of 5 relapsed patients. These cell lines maintained a high expression of CD49f/CD29 and ABCG2 antigens for more than 15 culture passages (range 20–75% and 20–42%, respectively). Conclusions. Our data indicate that tumor relapse was associated to the presence of CD49f/CD29 positive cells, which have been previously indicated as hepatic stem cell markers. The expression of ABCG2, a multi-drug resistence protein, could indicate a more aggressive tumor cells, i.e. putative CSCs. It remains to be assessed if the generation of cell lines in vitro could be useful to predict tumor relapse.

Published
2009
Full Text
View/download PDF

15. Osteopontin-IgM in the diagnosis of HCC

Author

Biasiolo, A., primary, Tono, N., additional, Franzosi, L., additional, Beneduce, L., additional, Zuin, J., additional, Fassina, G., additional, Meo, S., additional, Paccagnella, D., additional, Mazzucco, M., additional, Farinati, F., additional, Giacomin, A., additional, Vanin, V., additional, Aldinio, M.T., additional, Miola, E., additional, Donà, S., additional, Gatta, A., additional, and Pontisso, P., additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results